Abstracts

INPATIENT OUTCOMES FOR HIV-INFECTED PATIENTS HOSPITALIZED FOR ACUTE CORONARY SYNDROME

HIV-infected adults have excess morbidity and mortality from cardiovascular disease. Differences in the presentation and management of acute coronary syndromes (ACS) in this population may drive these findings. We hypothesized that HIV-infected adults admitted with ACS are less likely to receive percutaneous coronary intervention and have greater adverse outcomes compared with uninfected patients. This was…

PHENOTYPIC CLUSTERING OF HIV-ASSOCIATED ATHEROSCLEROSIS AND AGE-RELATED OUTCOMES

People with HIV (PWH) have increased cardiovascular disease risk, but the underlying mechanisms are not fully elucidated. We used machine learning to develop phenotypic profiles of individuals with subclinical carotid atherosclerosis that incorporate multiple risk factor interactions, and determined whether these profiles differentially associate with age-related disease. The MACS/WIHS CCS prospectively follows people with and…

ASSOCIATION OF INFLAMMATORY MARKERS WITH CARDIAC INDICES IN THE MACS

People living with HIV (HIV+) are at increased risk of heart failure even after adjustment for demographics and cardiovascular risk factors. Among HIV+ without symptoms of heart failure, diastolic dysfunction has been reported to be highly prevalent. We hypothesized diastolic dysfunction to be an early marker of myocardial disease related to heightened inflammation in HIV…

PRESENTATION OF HVTN 702 STUDY DATA

On February 3, 2020 the HVTN 702 HIV vaccine efficacy trial in South Africa discontinued vaccinations because the interim review by the Data and Safety Monitoring Board reported that the vaccine candidate did not prevent HIV. There were no safety concerns. Dr Glenda Gray described the results available from the HVTN 702 Study.